Immunotherapy plus chemo before stomach cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests combining immunotherapy (PD-1 blockers) with chemotherapy before surgery for advanced stomach cancer. The goal is to find the best number of treatment cycles to shrink the tumor and improve surgery results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 90 years old.
- You have stomach cancer or cancer where the stomach meets the esophagus (confirmed by biopsy).
- Your cancer can be removed with surgery (based on scans or a scope test).
- You have not had chemotherapy, radiation, or immunotherapy before.
- You have not had any other cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from coming back. You may qualify if you had D2 surgery and your tumor tested positive for PD-L1.
This trial tests a new immunotherapy drug (Retlirafusp Alfa) combined with chemotherapy before surgery for stomach or gastroesophageal junction cancer. It aims to shrink the tumor enough to allow surgery, and is for patients with specific types of HER2-negative or low-HER2 cancer and a PD-L1 CPS score of 1 or higher.
This trial studies whether adding a PD-1 immune therapy to chemotherapy around the time of surgery can improve outcomes for people with locally advanced stomach or stomach–esophagus junction cancer. It aims to better control the cancer before and reduce the chance it comes back after surgery.
This trial tests a combination of chemotherapy drugs (nab-paclitaxel, oxaliplatin, and S-1) plus an immunotherapy drug (sintilimab) given before surgery for younger people (ages 16 to 45) with stomach or gastroesophageal junction cancer that can be removed. The goal is to see if this approach shrinks tumors and improves outcomes.
This trial tests whether combining immunotherapy with chemotherapy before surgery can help treat adenocarcinoma of the esophagus and stomach junction. It aims to improve outcomes for patients whose cancer can be surgically removed.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.